OVOCA BIO PLC (OVXA.I) Stock Price, Forecast & Analysis
Europe - Euronext Dublin - DUB:OVXA - IE00B4XVDC01 - Common Stock
OVXA.I Key Statistics, Chart & Performance
The current stock price of OVXA.I is 0.0105 EUR. In the past month the price decreased by -57.14%. In the past year, price decreased by -93.4%.
OVXA.I Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| SNW.DE | SANOFI | 10.84 | 200.10B | ||
| 1SAN.MI | SANOFI | 10.75 | 198.47B | ||
| SAN.PA | SANOFI | 10.74 | 198.23B | ||
| MRK.DE | MERCK KGAA | 14.13 | 52.41B | ||
| 1MRK.MI | MERCK KGAA | 13.94 | 51.72B | ||
| UNC.DE | UCB SA | 37.51 | 46.84B | ||
| UCB.BR | UCB SA | 36.68 | 45.81B | ||
| BAYN.DE | BAYER AG-REG | 6.73 | 35.31B | ||
| 1BAYN.MI | BAYER AG-REG | 6.65 | 34.87B | ||
| REC.MI | RECORDATI INDUSTRIA CHIMICA | 24.71 | 10.18B | ||
| IPN.PA | IPSEN | 11.68 | 10.06B | ||
| TUB.BR | FINANCIERE DE TUBIZE | 100.48 | 9.30B |
Related stock screener links
About OVXA.I
Company Profile
Ovoca Bio Plc is a clinical-stage biopharmaceutical company, which engages in the women's health, clinical development and commercial planning of BP-101, and novel treatment for women with hypoactive sexual desire disorder (HSDD). The firm is developing Orenetide, a novel medicinal treatment for premenopausal women with hypoactive sexual desire disorder (HSDD). The company is focused on women’s health and identifying novel candidates in areas of high unmet medical need. The Company’s lead product, Orenetide (BP-101), is a novel synthetic peptide for the treatment of HSDD and is conveniently administered through a nasal spray. The spray delivers the drug to olfactory and trigeminal nerves in the nasal cavity where the drug accumulates in the olfactory bulb and further in the brain. The company is also developing a new treatment for women affected by low libido or sex drive. The company owns a patent portfolio that provides effective protection of its technology. The firm operates in Ireland, the United Kingdom and Russia.
Company Info
OVOCA BIO PLC
17 Pembroke Street, Upper
DUBLIN DUBLIN IE
Employees: 5
Phone: 35316619819
OVOCA BIO PLC / OVXA.I FAQ
Can you describe the business of OVOCA BIO PLC?
Ovoca Bio Plc is a clinical-stage biopharmaceutical company, which engages in the women's health, clinical development and commercial planning of BP-101, and novel treatment for women with hypoactive sexual desire disorder (HSDD). The firm is developing Orenetide, a novel medicinal treatment for premenopausal women with hypoactive sexual desire disorder (HSDD). The company is focused on women’s health and identifying novel candidates in areas of high unmet medical need. The Company’s lead product, Orenetide (BP-101), is a novel synthetic peptide for the treatment of HSDD and is conveniently administered through a nasal spray. The spray delivers the drug to olfactory and trigeminal nerves in the nasal cavity where the drug accumulates in the olfactory bulb and further in the brain. The company is also developing a new treatment for women affected by low libido or sex drive. The company owns a patent portfolio that provides effective protection of its technology. The firm operates in Ireland, the United Kingdom and Russia.
Can you provide the latest stock price for OVOCA BIO PLC?
The current stock price of OVXA.I is 0.0105 EUR. The price decreased by -8.7% in the last trading session.
What is the dividend status of OVOCA BIO PLC?
OVXA.I does not pay a dividend.
What is the ChartMill rating of OVOCA BIO PLC stock?
OVXA.I has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Where is OVOCA BIO PLC (OVXA.I) stock traded?
OVXA.I stock is listed on the Euronext Dublin exchange.
Can you provide the market cap for OVOCA BIO PLC?
OVOCA BIO PLC (OVXA.I) has a market capitalization of 928.83K EUR. This makes OVXA.I a Nano Cap stock.
OVXA.I Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to OVXA.I. When comparing the yearly performance of all stocks, OVXA.I is a bad performer in the overall market: 98.78% of all stocks are doing better.
OVXA.I Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to OVXA.I. While OVXA.I has a great health rating, there are worries on its profitability.
OVXA.I Financial Highlights
Over the last trailing twelve months OVXA.I reported a non-GAAP Earnings per Share(EPS) of -0.06. The EPS increased by 9.01% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -151.63% | ||
| ROE | -210% | ||
| Debt/Equity | 0 |